Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.
- DOI
- 10.1111/his.70285
- Published
- 2026 Sep 24
- Container
- Histopathology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/his.70285,
title = {Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.},
author = {Koh J and Suh KJ and Park HY and Kwon HJ and Sung HJ and Ryu HS and Kim JH and Koh J and Lee KH and Lee DW and Park C and Seo J and Chae H and Hwang W and Suh YY and Ahn CH and Im SA and Kim JH and Park SY},
year = {2026},
journal = {Histopathology},
doi = {10.1111/his.70285},
url = {https://doi.org/10.1111/his.70285}
}RIS
TY - JOUR TI - Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance. AU - Koh J AU - Suh KJ AU - Park HY AU - Kwon HJ AU - Sung HJ AU - Ryu HS AU - Kim JH AU - Koh J AU - Lee KH AU - Lee DW AU - Park C AU - Seo J AU - Chae H AU - Hwang W AU - Suh YY AU - Ahn CH AU - Im SA AU - Kim JH AU - Park SY PY - 2026 JO - Histopathology DO - 10.1111/his.70285 UR - https://doi.org/10.1111/his.70285 ER -
APA
J, K., KJ, S., HY, P., HJ, K., HJ, S., HS, R., JH, K., J, K., KH, L., DW, L., C, P., J, S., H, C., W, H., YY, S., CH, A., SA, I., JH, K., & SY, P. (2026). Heterogeneity of breast and nodal response to neoadjuvant pembrolizumab-based chemoimmunotherapy in early triple-negative breast cancer and its clinical significance.. Histopathology. https://doi.org/10.1111/his.70285
Source records
- pubmed · retrieved 2026-09-25T22:42:08.960Z